Aurobindo Pharma's Subsidiary CuraTeQ Biologics Receives Approval for Biosimilar Zefylti from UK's MHRA

Aurobindo Pharma Ltd announced that its step-down wholly owned subsidiary, CuraTeQ Biologics s.r.o, has obtained marketing authorisation from UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for Zefylti®, its filgrastim biosimilar version. This approval follows the marketing authorisation received in the European Union from the European Commission (EC) in February 2025. Zefylti® is CuraTeQ’s second biosimilar to be approved by MHRA. CuraTeQ Biologics Private Limited, a global biopharmaceutical company, is focused on developing biosimilars for the treatment of various cancers and autoimmune diseases. Its pipeline consists of fourteen biosimilars, primarily targeting the immunology and oncology segments. Aurobindo Pharma Limited, the parent company, is an integrated global pharmaceutical company that develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally.